Negri A, Javidnia P, Mu R, Zhang X, Vendome J, Gold B, Roberts J, Barman D, Ioerger T, Sacchettini JC et al..
2018.
Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosis.. ACS Infect Dis. 4(5):771-787.
Early J, Ollinger J, Darby C, Alling T, Mullen S, Casey A, Gold B, Ochoada J, Wiernicki T, Masquelin T et al..
2019.
Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis.. ACS Infect Dis. 5(2):272-280.
MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan C.
1997.
Identification of nitric oxide synthase as a protective locus against tuberculosis.. Proc Natl Acad Sci U S A. 94(10):5243-8.
Nathan C.
2017.
Introduction of Laurie H. Glimcher, MD.. J Clin Invest. 127(10):3575.
Lin G, Chidawanyika T, Tsu C, Warrier T, Vaubourgeix J, Blackburn C, Gigstad K, Sintchak M, Dick L, Nathan C.
2013.
N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.. J Am Chem Soc. 135(27):9968-71.
Warrier T, Kapilashrami K, Argyrou A, Ioerger TR, Little D, Murphy KC, Nandakumar M, Park S, Gold B, Mi J et al..
2016.
N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 113(31):E4523-30.
Gold B, Smith R, Nguyen Q, Roberts J, Ling Y, Quezada LLopez, Somersan S, Warrier T, Little D, Pingle M et al..
2016.
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.. J Med Chem. 59(13):6027-44.
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Resto YAlemán, Alsibaee A, Alzualde A et al..
2016.
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.. PLoS Pathog. 12(7):e1005763.
Nathan C.
2002.
Points of control in inflammation.. Nature. 420(6917):846-52.
K Darwin H, Ehrt S, Gutierrez-Ramos J-C, Weich N, Nathan CF.
2003.
The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide.. Science. 302(5652):1963-6.
Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan C, Sauer RT, Sello JK.
2017.
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.. ACS Infect Dis. 3(2):176-181.
Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J et al..
2017.
Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.. Proc Natl Acad Sci U S A. 114(24):E4832-E4840.